PA
LUMO

Perceptive Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Perceptive Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-50,000
Closed -$3.65M – 155
2017
Q4 		$3.65M Hold
50,000
– – 0.12% 78
2017
Q3 		$4.58M Buy
+50,000
New +$3.83M 0.18% 73

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Perceptive Advisors's LUMO Position: Q1 2018 in Review

Perceptive Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2018, closing a stake of 50,000 shares — an estimated $3.65M sold.

Perceptive Advisors first reported a position in LUMO in Q3 2017 and held it in 2 quarters. The position peaked at $4.58M in Q3 2017. 126 funds tracked by Wall St. Rank hold LUMO as of Q1 2018.

  • Perceptive Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Perceptive Advisors sold 50,000 Lumos Pharma, Inc. Common Stock shares in Q1 2018, an estimated $3.65M.
  • Perceptive Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2017 and held it in 2 quarters.
  • Perceptive Advisors's Lumos Pharma, Inc. Common Stock position peaked at $4.58M in Q3 2017.
  • 126 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2018.

Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.